Autism spectrum disorders (ASDs) are common, debilitating disorders affecting social interaction, communication, and repetitive behaviors. Recent genetic findings have identified mutations in synaptic cell adhesion genes and genes encoding their interacting protein partners at central synapses as genetic causes of autism spectrum disorders. We have created a novel autism model mouse line based on deletion of neuroligin-1. These mice have selective, excessive repetitive behavioral abnormalities of potential relevance to autism. Our preliminary data strongly implicate a decrease in NMDA receptor function in the striatum as a cause of this repetitive behavior phenotype. We now propose experiments to examine the effect of deletion of this gene on cortico-striatal synaptic function in detail. Furthermore, we propose to selectively rescue/treat this phenotype using genetic and pharmacologic approaches. Thus, we will be able to directly connect a specific synapse in a specific brain region due to a specific molecular abnormality with an abnormal behavior, an important basic goal in neuroscience. These experiments will identify novel synaptic and circuit-level mechanisms for obsessive-compulsive disorder- like repetitive behaviors in general. In addition, we hope to identify novel treatment targets for these behaviors for a subset of autistic patients.
Our goal is to better understand genetic causes of human autism and to use animal models of such causes to identify treatments. This R01 proposal capitalizes on our recent progress examining a novel genetic autism- relevant model. This model exhibits excessive stereotyped repetitive behaviors characteristic of autism. Our experiments will directly link abnormalities in brain function in a specific brain region with these abnormal behaviors and allow us to identify novel treatment targets for a subset of autism and perhaps other disorders with obsessive-compulsive-like behavioral differences. Ultimately, such treatments could be tested directly in patients.
|Goodspeed, Kimberly; Newsom, Cassandra; Morris, Mary Ann et al. (2018) Pitt-Hopkins Syndrome: A Review of Current Literature, Clinical Approach, and 23-Patient Case Series. J Child Neurol 33:233-244|
|Jaramillo, Thomas C; Escamilla, Christine Ochoa; Liu, Shunan et al. (2018) Genetic background effects in Neuroligin-3 mutant mice: Minimal behavioral abnormalities on C57 background. Autism Res 11:234-244|
|Powell, Craig M (2017) Neuroscience: Mum's bacteria linked to baby's behaviour. Nature 549:466-467|
|Escamilla, Christine Ochoa; Filonova, Irina; Walker, Angela K et al. (2017) Kctd13 deletion reduces synaptic transmission via increased RhoA. Nature 551:227-231|
|Araujo, Daniel J; Toriumi, Kazuya; Escamilla, Christine O et al. (2017) Foxp1 in Forebrain Pyramidal Neurons Controls Gene Expression Required for Spatial Learning and Synaptic Plasticity. J Neurosci 37:10917-10931|
|Celen, Cemre; Chuang, Jen-Chieh; Luo, Xin et al. (2017) Arid1b haploinsufficient mice reveal neuropsychiatric phenotypes and reversible causes of growth impairment. Elife 6:|
|Fernandes, Darren J; Ellegood, Jacob; Askalan, Rand et al. (2017) Spatial gene expression analysis of neuroanatomical differences in mouse models. Neuroimage 163:220-230|
|Powell, Craig M (2016) Autism Screening or Smoke Screen and Mirrors? JAMA Neurol 73:386-7|
|Espinosa, Felipe; Xuan, Zhong; Liu, Shunan et al. (2015) Neuroligin 1 modulates striatal glutamatergic neurotransmission in a pathway and NMDAR subunit-specific manner. Front Synaptic Neurosci 7:11|
|Latchney, Sarah E; Jaramillo, Thomas C; Rivera, Phillip D et al. (2015) Chronic P7C3 treatment restores hippocampal neurogenesis in the Ts65Dn mouse model of Down Syndrome [Corrected]. Neurosci Lett 591:86-92|
Showing the most recent 10 out of 20 publications